Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms

In myeloproliferative neoplasms (MPNs) the incidence of venous thromboembolism (VTE) is 0.6–1.0 per 100 pt-years, and the rate of recurrence after VTE is 6.0–6.5 per 100 pt-yrs. Vitamin K-antagonists (VKA) reduces the risk of recurrence after VTE at usual sites (i.e., deep venous thrombosis (DVT) of...

Descripción completa

Detalles Bibliográficos
Autores principales: De Stefano, Valerio, Finazzi, Guido, Barbui, Tiziano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Current Treatment Algorithm
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018810/
https://www.ncbi.nlm.nih.gov/pubmed/29946112
http://dx.doi.org/10.1038/s41408-018-0101-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018810/
https://www.ncbi.nlm.nih.gov/pubmed/29946112
http://dx.doi.org/10.1038/s41408-018-0101-8

Ejemplares similares